Venture Capital To Indian Biotechs Lagging This Year
This article was originally published in PharmAsia News
Venture capital investments in Indian biotechs have dropped, according to a report on the first quarter of this year. Dow Jones VentureSources counted $11 million invested in only two biopharmaceutical deals during that three-month period. Last year, $99.5 million was invested in life sciences and health care companies in India. An official at MPM Capital, which with TPG Ventures, was among early investors in early-stage biotechs in India, says he still expects the number of life sciences deals to grow. (Click here for more
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.